Skip to content

A randomized double-blind placebo-controlled study of XLF intervention in people with essential hypertension and high salt (phlegm-dampness syndrome).

A randomized double-blind placebo-controlled study of XLF intervention in people with essential hypertension and high salt (phlegm-dampness syndrome).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000079
Enrollment
Unknown
Registered
2025-01-13
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

Control Group:Placebo
Experimental Group:XLF

Sponsors

Beijing Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for essential hypertension and there is no limit to grade 1 2 and 3 hypertension. (2) Meet the evaluation criteria of high salt intake that is people with salt intake > 10g/d; (3) meet the diagnostic criteria for phlegm turbidity syndrome; (4) Age 18-80 years old gender is not limited; (5) Patients and their families agree to participate in the trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with uncontrolled severe hypertension or hypertensive emergencies and subemergencies. (2) Patients with secondary hypertension. (3) Patients with acute coronary syndrome or acute heart failure/acute exacerbation of chronic heart failure valvular heart disease with obvious hemodynamic changes and severe malignant arrhythmias or patients with cardiomyopathy pulmonary heart disease viral myocarditis and congenital heart disease; (4) Patients with hyperthyroidism malignant tumors hematologic diseases and acute infections; (5) Women who are pregnant or lactating; (6) Abnormal liver function (ALT or AST higher than the upper limit of normal) abnormal renal function (Cr>3mg/dl); (7) Patients with mental illness or cognitive and memory impairments; (8) Patients who are unable to cooperate with the completion of TCM-related symptoms tongue and pulse information collection and questionnaire surveys (9) Any other condition that the investigator considers the patient to be unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
BP qualified rate;

Secondary

MeasureTime frame
Target organ damage;BP effective rate;TCM syndrome score;TCMSS effective rate;

Countries

China

Contacts

Public ContactLiu Hongxu

Beijing Hospital of Traditional Chinese Medicine

lhx_@263.net87906633

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026